Medexus Pharmaceuticals Inc. P731.F Stock
Medexus Pharmaceuticals Inc. Price Chart
Medexus Pharmaceuticals Inc. P731.F Financial and Trading Overview
| Medexus Pharmaceuticals Inc. stock price | 1.03 EUR |
| Previous Close | 0.82 EUR |
| Open | 0.83 EUR |
| Bid | 0.84 EUR x 0 |
| Ask | 0.86 EUR x 0 |
| Day's Range | 0.83 - 0.83 EUR |
| 52 Week Range | 0.67 - 2.36 EUR |
| Volume | 3.06K EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 17.24M EUR |
| Beta (5Y Monthly) | 1.669071 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0.27 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
P731.F Valuation Measures
| Enterprise Value | 72.7M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.17284468 |
| Price/Book (mrq) | 1.0835509 |
| Enterprise Value/Revenue | 0.729 |
| Enterprise Value/EBITDA | 6.805 |
Trading Information
Medexus Pharmaceuticals Inc. Stock Price History
| Beta (5Y Monthly) | 1.669071 |
| 52-Week Change | -45.63% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.36 EUR |
| 52 Week Low | 0.67 EUR |
| 50-Day Moving Average | 0.91 EUR |
| 200-Day Moving Average | 1.17 EUR |
P731.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 20.14M |
| Float | 17.02M |
| Short Ratio | N/A |
| % Held by Insiders | 11.39% |
| % Held by Institutions | 0.37% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | March 31, 2023 |
Profitability
| Profit Margin | -10.95% |
| Operating Margin (ttm) | 4.97% |
| Gross Margin | 61.03% |
| EBITDA Margin | 10.71% |
Management Effectiveness
| Return on Assets (ttm) | 2.18% |
| Return on Equity (ttm) | -56.63% |
Income Statement
| Revenue (ttm) | 99.73M EUR |
| Revenue Per Share (ttm) | 5.01 EUR |
| Quarterly Revenue Growth (yoy) | 35.09% |
| Gross Profit (ttm) | 43.67M EUR |
| EBITDA | 10.68M EUR |
| Net Income Avi to Common (ttm) | -10922000 EUR |
| Diluted EPS (ttm) | -0.53 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 9.27M EUR |
| Total Cash Per Share (mrq) | 0.46 EUR |
| Total Debt (mrq) | 65.66M EUR |
| Total Debt/Equity (mrq) | 425.6 EUR |
| Current Ratio (mrq) | 0.614 |
| Book Value Per Share (mrq) | 0.766 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -1525000 EUR |
| Levered Free Cash Flow (ttm) | -7859500 EUR |
Profile of Medexus Pharmaceuticals Inc.
| Country | Germany |
| State | ON |
| City | Bolton |
| Address | 35 Nixon Road |
| ZIP | L7E 1K1 |
| Phone | 877 633 3987 |
| Website | https://www.medexus.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 100 |
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
Q&A For Medexus Pharmaceuticals Inc. Stock
What is a current P731.F stock price?
Medexus Pharmaceuticals Inc. P731.F stock price today per share is 1.03 EUR.
How to purchase Medexus Pharmaceuticals Inc. stock?
You can buy P731.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Medexus Pharmaceuticals Inc.?
The stock symbol or ticker of Medexus Pharmaceuticals Inc. is P731.F.
Which industry does the Medexus Pharmaceuticals Inc. company belong to?
The Medexus Pharmaceuticals Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Medexus Pharmaceuticals Inc. have in circulation?
The max supply of Medexus Pharmaceuticals Inc. shares is 25.55M.
What is Medexus Pharmaceuticals Inc. Price to Earnings Ratio (PE Ratio)?
Medexus Pharmaceuticals Inc. PE Ratio is 3.81481460 now.
What was Medexus Pharmaceuticals Inc. earnings per share over the trailing 12 months (TTM)?
Medexus Pharmaceuticals Inc. EPS is 0.27 EUR over the trailing 12 months.
Which sector does the Medexus Pharmaceuticals Inc. company belong to?
The Medexus Pharmaceuticals Inc. sector is Healthcare.